Repurposing metocurine as main protease inhibitor to develop novel antiviral therapy for COVID-19
© Springer Science+Business Media, LLC, part of Springer Nature 2020..
The outbreak of severe acute respiratory syndrome coronavirus-2 is causing a serious disaster through coronavirus disease-19 (COVID-19) around the globe. A large segment of the population from every corner of the world is already infected with this dreadful pathogen with a high mortality rate. These numbers are increasing drastically causing a situation of a global pandemic. Although after the continuous scientific efforts, we are still not having any specific drug or vaccine for the SARS-CoV-2 pathogen to date and there is an urgent need to develop a newer therapy to counter the COVID-19 global pandemic. Thus, in the current study, a framework for computational drug repurposing is established, and based on their safety profile, metocurine was chosen as a safe and effective drug candidate for developing therapy against the viral Mpro enzyme of SARS-CoV-2 for the treatment of COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:31 |
|---|---|
| Enthalten in: |
Structural chemistry - 31(2020), 6 vom: 15., Seite 2487-2499 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jain, Rashi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antiviral |
|---|
| Anmerkungen: |
Date Revised 30.06.2022 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1007/s11224-020-01605-w |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM314105603 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM314105603 | ||
| 003 | DE-627 | ||
| 005 | 20231225152019.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11224-020-01605-w |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1046.xml |
| 035 | |a (DE-627)NLM314105603 | ||
| 035 | |a (NLM)32837119 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jain, Rashi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Repurposing metocurine as main protease inhibitor to develop novel antiviral therapy for COVID-19 |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 30.06.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © Springer Science+Business Media, LLC, part of Springer Nature 2020. | ||
| 520 | |a The outbreak of severe acute respiratory syndrome coronavirus-2 is causing a serious disaster through coronavirus disease-19 (COVID-19) around the globe. A large segment of the population from every corner of the world is already infected with this dreadful pathogen with a high mortality rate. These numbers are increasing drastically causing a situation of a global pandemic. Although after the continuous scientific efforts, we are still not having any specific drug or vaccine for the SARS-CoV-2 pathogen to date and there is an urgent need to develop a newer therapy to counter the COVID-19 global pandemic. Thus, in the current study, a framework for computational drug repurposing is established, and based on their safety profile, metocurine was chosen as a safe and effective drug candidate for developing therapy against the viral Mpro enzyme of SARS-CoV-2 for the treatment of COVID-19 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Antiviral | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Corona | |
| 650 | 4 | |a Drug repositioning | |
| 650 | 4 | |a Drug repurposing | |
| 650 | 4 | |a SARS-CoV-2 | |
| 700 | 1 | |a Mujwar, Somdutt |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Structural chemistry |d 2009 |g 31(2020), 6 vom: 15., Seite 2487-2499 |w (DE-627)NLM220114358 |x 1040-0400 |7 nnns |
| 773 | 1 | 8 | |g volume:31 |g year:2020 |g number:6 |g day:15 |g pages:2487-2499 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s11224-020-01605-w |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 31 |j 2020 |e 6 |b 15 |h 2487-2499 | ||